Minimizing Pharmaceuticals in the Environment
As a pharmaceutical company and member of the global community, Mylan is committed to caring for the environment and promoting responsible manufacturing by taking steps to minimize the environmental impact of our operations and products, while also balancing our need to produce high quality, life-saving medication.
The primary pathways for pharmaceuticals entering the environment from human use are by normal patient excretion and improper disposal of medicine by consumers,1 in addition to the use of pharmaceuticals in agriculture. A significantly smaller contribution stems from emissions resulting from the pharmaceutical manufacturing process, which is attributed to less than 2% of the overall contribution.2
While gaps remain in the scientific link between pharmaceuticals in the environment and human health risk, we are committed to reducing pharmaceuticals discharged from our manufacturing operations.
Mylan’s approach to addressing and minimizing the potential impact of PiE from our own manufacturing is based on a wide range of activities and governance including:
We are a member of the AMR Industry Alliance. All member companies are committed to addressing AMR across four key areas: research, appropriate use, access and manufacturing and the environment. Mylan participates in their manufacturing working group and supports the Common Antibiotic Manufacturing Framework.
1Caldwell, D.J. (2015) Sources of Pharmaceutical Residues in the Environment and their Control, from ‘Pharmaceuticals in the Environment’, 2015, 92- 119 Editor(s): R E Hester, R M Harrison. Royal Society of Chemistry, London, UK.
2BIO Intelligence Service (2013), Study on the environmental risks of medicinal products, final report prepared for Executive Agency for Health and Consumers, pp. 46-47.